ClinicalTrials.gg

Program

Tetrodotoxin

Also written as “Halneuron”.

Its studies are mostly in Pain · Neuralgia, led by 2 companies.

Furthest: phase 3, since Jul 28, 20087 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Wex Pharmaceuticals60 open or runningphase 3since Jul 28, 2008Jul 28, 2008none ahead
Dogwood Therapeutics11 open or runningphase 2since Feb 3, 2025Feb 3, 2025Dec 2026phase 2 · NCT06848348

Also a collaborator on its studies: celerion and premier-research-group-plc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 28, 2008First studies: 2 phase 3 studies in PainNew to Wex PharmaceuticalsWex Pharmaceuticals · NCT00726011, NCT00725114
  2. Jan 23, 2012Phase 1 study in HealthyWex Pharmaceuticals · NCT01527734 · 44 enrolled · United States
  3. Jul 19, 2012Phase 2 study in PainWex Pharmaceuticals · NCT01655823 · 125 enrolled · United States
  4. Sep 6, 2019Phase 1 study in TQT StudyWex Pharmaceuticals · NCT04083833 · 25 enrolled · United States
  5. Apr 25, 2022Phase 2 study in PainWex Pharmaceuticals · NCT05359133 · 35 enrolled · United States
  6. Feb 3, 2025Dogwood Therapeutics's first study: phase 2 study in PainNew to Dogwood TherapeuticsDogwood Therapeutics · NCT06848348 · 240 enrolled · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in PainDogwood Therapeutics · NCT06848348

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06848348Pain · United States2Active, not recruitingDogwood TherapeuticsDec 2026240
NCT05359133Pain · United States2TerminatedWex PharmaceuticalsOct 14, 202435
NCT04083833TQT Study · United States1CompletedWex PharmaceuticalsMar 24, 201825
NCT01655823Pain · United States2TerminatedWex PharmaceuticalsJan 2015125
NCT01527734Healthy · United States1CompletedWex PharmaceuticalsJan 201244
NCT00726011Pain · Canada3CompletedWex PharmaceuticalsDec 2011113
NCT00725114Pain · Canada3CompletedWex PharmaceuticalsNov 2012165

How it is read

Names in the registry

  • “Tetrodotoxin”, 6 entries
  • “Halneuron”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.